Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
:ZTS
ZTS Stock Chart & Stats
$128.18
$1.04(0.64%)
At close: 4:00 PM EST
$128.18
$1.04(0.64%)
Day’s Range― - ―
52-Week Range$115.25 - $181.85
Previous CloseN/A
Volume625.10K
Average Volume (3M)4.52M
Market Cap
$56.49B
Enterprise Value$70.04B
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$7.27B
Price to Earnings (P/E)21.6
Beta0.57
Next Earnings
Feb 17, 2026EPS Estimate
1.41Last Dividend Ex-Date
Oct 31, 2025Dividend Yield1.56%
Share Statistics
EPS (TTM)1.70
Shares Outstanding440,693,200
10 Day Avg. Volume5,104,699
30 Day Avg. Volume4,518,367
Financial Highlights & Ratios
PEG Ratio3.88
Price to Book (P/B)15.51
Price to Sales (P/S)8.00
P/FCF Ratio32.20
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue7.45
Enterprise Value/Gross Profit10.55
Enterprise Value/Ebitda17.29
Forecast
1Y Price Target
$167.25Price Target Upside30.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)6.34
Revenue Forecast (FY)$9.45B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe operating margin expanded and was above plan, indicating stronger profitability for Zoetis.
Innovation PipelineZoetis continued to advance its innovation pipeline, with positive approvals and launches expected for new products.
Product LaunchesZoetis plans to roll out Lenivia, the first monoclonal antibody to alleviate OA pain in dogs for 3 months, in Canada/EU, which is viewed as a source of convenience for pet owners.
Bears Say
Competition ConcernsLingering concerns about competition have weighed on sentiment, compounded by Librela commercial hiccups.
Earnings GuidanceThe lowered 2025 operational guidance will be in focus, highlighting concerns about US Librela sales falling short of expectations.
Market ChallengesThe big surprise was the slowdown in the company's US bread-and-butter companion animal health segment, which came in flat, as the company cited a step-up in competitive activity and a decline in vet clinic visits.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $115.25 and its highest was $181.85 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $56.49B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Feb 17, 2026 which is in 78 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Nov 04, 2025. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.621 by $0.079.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.5 which represents an annual dividend yield of 1.56%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.41.
How many shares outstanding does Zoetis have?
Zoetis has 440,693,200 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.7 in its last earnings report, beating expectations of $1.621. Following the earnings report the stock price went down -13.779%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
Zoetis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$167.25 (30.48% Upside)
$167.25 (30.48% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.51%
12-Months-Change
Fundamentals
Return on Equity
49.87%
Trailing 12-Months
Asset Growth
5.59%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. (ZTS) is a global leader in animal health, dedicated to supporting the health and well-being of livestock and companion animals. Founded in 1952, the company develops and manufactures a wide range of veterinary medicines, vaccines, and diagnostic products. Zoetis operates in various sectors including livestock, such as cattle, swine, and poultry, as well as companion animals like dogs and cats. Its core products include parasiticides, anti-infectives, vaccines, and nutritional products, all aimed at enhancing animal health and productivity.
ZTS Company Deck
ZTS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Zoetis demonstrated strong performance in international markets and Livestock segment growth, with new product approvals enhancing future prospects. However, challenges in the OA pain franchise, U.S. market pressures, and competitive dynamics in dermatology posed significant headwinds.View all ZTS earnings summariesZTS Revenue Breakdown
23.26% Parasiticides
19.74% Vaccines
17.88% Dermatology
11.88% Anti-infectives
27.24% Other
ZTS Stock 12 Month Forecast
Average Price Target
$167.25
▲(30.48% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
19.30% Mutual Funds
21.18% Other Institutional Investors
34.43% Public Companies and Individual Investors